Bristol Myers Squibb Stock Performance
| BMYMP Stock | USD 935.22 0.00 0.00% |
Bristol-Myers Squibb has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.26, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Bristol-Myers Squibb are expected to decrease at a much lower rate. During the bear market, Bristol-Myers Squibb is likely to outperform the market. Bristol Myers Squibb right now shows a risk of 2.92%. Please confirm Bristol Myers Squibb coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if Bristol Myers Squibb will be following its price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile primary indicators, Bristol-Myers Squibb may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
| Begin Period Cash Flow | 15 B | |
| Total Cashflows From Investing Activities | -538 M |
Bristol-Myers |
Bristol-Myers Squibb Relative Risk vs. Return Landscape
If you would invest 87,728 in Bristol Myers Squibb on November 1, 2024 and sell it today you would earn a total of 5,794 from holding Bristol Myers Squibb or generate 6.6% return on investment over 90 days. Bristol Myers Squibb is currently producing 0.1448% returns and takes up 2.9188% volatility of returns over 90 trading days. Put another way, 26% of traded pink sheets are less volatile than Bristol-Myers, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Bristol-Myers Squibb Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bristol-Myers Squibb's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bristol Myers Squibb, and traders can use it to determine the average amount a Bristol-Myers Squibb's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0496
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | BMYMP | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.92 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Bristol-Myers Squibb is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bristol-Myers Squibb by adding it to a well-diversified portfolio.
Bristol-Myers Squibb Fundamentals Growth
Bristol-Myers Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bristol-Myers Squibb, and Bristol-Myers Squibb fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bristol-Myers Pink Sheet performance.
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B | |||
| Total Asset | 109.31 B | |||
About Bristol-Myers Squibb Performance
Assessing Bristol-Myers Squibb's fundamental ratios provides investors with valuable insights into Bristol-Myers Squibb's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bristol-Myers Squibb is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.Things to note about Bristol Myers Squibb performance evaluation
Checking the ongoing alerts about Bristol-Myers Squibb for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bristol Myers Squibb help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Bristol-Myers Squibb's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Bristol-Myers Squibb's pink sheet performance include:- Analyzing Bristol-Myers Squibb's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bristol-Myers Squibb's stock is overvalued or undervalued compared to its peers.
- Examining Bristol-Myers Squibb's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bristol-Myers Squibb's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bristol-Myers Squibb's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bristol-Myers Squibb's pink sheet. These opinions can provide insight into Bristol-Myers Squibb's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bristol-Myers Pink Sheet Analysis
When running Bristol-Myers Squibb's price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.